Multiple Myeloma
Kenneth Carl Anderson, Melissa Alsina, William Bensinger et al. · Journal of the National Comprehensive Cancer Network · 2009
OverviewMultiple myeloma (MM) is a malignant neoplasm of plasma cells that accumulate in bone marrow, leading to bone destruction and marrow failure.The American Cancer Society estimates that 20,580 new cases of MM will occur in the United States in 2009, including 11,680 in men and 8900 in women, with an estimated 10,580 deaths. 1 The mean age of affected individuals is 62 years for men (75% > 70 years) and 61 years for women (79% > 70 years).The treatment of MM has dramatically improved over the past decade.The 5-year survival rate reported in the Surveillance Epidemiology and End Results database has increased from 25% in 1975 to 34% in 2003 because of the availability of newer and more effective treatment options.2,
Cited by 226 works. doi:10.6004/jnccn.2009.0061 Open-access PDF
Authors
- Kenneth Carl Anderson
- Melissa Alsina
- William Bensinger
- Janet Sybil Biermann
- Asher Alban Chanan-Khan
- Adam D. Cohen
- Steven Michael Devine
- Benjamin Djulbegović
- Cristina Gasparetto
- Carol Ann Huff
- Madan Jagasia
- Bruno C. Medeiros
- Ruby F. Meredith
- Noopur S Raje
- Jeffrey R. Schriber
- Seema Singhal
- George Somlo
- Keith E Stockerl-Goldstein
- Guido J. K. Tricot
- Julie Marie Vose
References
- Antitumor Activity of Thalidomide in Refractory Multiple Myeloma
- A Prospective, Randomized Trial of Autologous Bone Marrow Transplantation and Chemotherapy in Multiple Myeloma
- International Staging System for Multiple Myeloma
- Efficacy of Pamidronate in Reducing Skeletal Events in Patients with Advanced Multiple Myeloma
- Review of 1027 Patients With Newly Diagnosed Multiple Myeloma
- Improved survival in multiple myeloma and the impact of novel therapies
- Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma
- Lenalidomide plus Dexamethasone for Relapsed or Refractory Multiple Myeloma
- Lenalidomide plus Dexamethasone for Relapsed Multiple Myeloma in North America
- Single versus Double Autologous Stem-Cell Transplantation for Multiple Myeloma